Skip to main content

Infrastructure for Personalized Medicine at Partners HealthCare.

Partners HealthCare Personalized Medicine (PPM) is central in partner systems HealthCare (founded by Massachusetts General Hospital and Brigham and Women's Hospital) whose mission is to utilize genetics and genomics to improve patient care in a cost effective manner.

 PPM consists of five interrelated Equine Clia Kitscomponents: (1) Laboratory of Molecular Medicine (LMM), CLIA laboratories perform genetic testing for patients around the world; (2) Translational Genomics Core (TGC), a core lab provides a platform for researchers Partners genome; (3) Options Biobank, a Biobank samples (DNA, plasma and serum) for 50,000 patients agree Partners; (4) Biobank Portal, IT infrastructure and the viewer to unify genotype, sample, phenotype (validated diagnosis, radiology, and clinical chemistry) of electronic medical records researchers Partners. These components are held together by (5) common IT system that brings researchers, clinicians, and patients together for optimal research and patient care.
Infrastructure for Personalized Medicine at Partners HealthCare.

Monitoring the process of measles elimination by serosurveillance data: The study Apulian 2012.


In 2003 Italy adopted a National Plan for the Elimination of Measles and Congenital Rubella, but some outbreaks of measles still occur, as the levels of target coverage (≥ 95%) of newborns General Clia Kits has not currently reached. In order to support the monitoring of measles elimination program, the authors conducted a survey on the seroprevalence of measles among young adults Apulia. This study was conducted from May 2011 to June 2012 among blood donors the Department of Transfusion Medicine General Hospital Policlinico di Bari. Subjects were enrolled by convenience sampling. For each patient enrolled we collect 5 mL serum sample. 

Collected sera were tested by chemiluminescence (CLIA) for anti-measles IgG. We enrolled 1764 subjects; 1362 (77.2%) were male with a mean age of 38.4 ± 11.7 years. Anti-measles IgG titer is >> 16.5UA / mL in 95.1% (95% CI = 94.1 to 96.1) of subjects enrolled with Geometric Mean Titre (GMT) 2.3 ± 0.4, which is not divide different registered till the age groups. As our data show, the universal routine vaccinations changing epidemiological pattern in adults, particularly young adults (18-24 years), which indicates the level of the lowest seropositivity; in groups of people there is a risk of outbreaks because of the presence of vulnerable population. 

It is a paradox associated with vaccination strategy: when the level of coverage keep sub-optimal, measles is more likely to affect young adults and a higher percentage of complications are expected. According to our data, health authorities should plan mop-up strategy to actively offer measles vaccination for young adults who are vulnerable.
Labels:

Comments

Post a Comment

Popular posts from this blog

Incidence of the 22q11.2 deletion in a large cohort of miscarriage samples.

BACKGROUND The 22q11.2 deletion syndrome is the most common microdeletion syndrome in live births, but data on the incidence in other populations is limited and also includes ascertainment bias. This study was designed to determine the incidence of miscarriage deletion 22q11.2  Human Clia Kits in samples sent for testing clinical molecular cytogenetics. RESULTS 6101 Twenty fresh products of conception (POC) samples were sent to CLIA- certified, CAP-accredited laboratory of April 2010 - May 2016 for miscarriage molecular cytogenetic testing using single nucleotide polymorphism (SNP) based microarray platform. A retrospective review determined 22q11.2 deletion events in this sample set. The results obtained in 22,451 fetuses (86%) cases, which, 15 (0.07%) had a microdeletion at 22q11.2 region (incidence, 1/1497). Of those, 12 (80%) cases were found in a sample of normal at a resolution karyotyping traditional (ie, no chromosomal abnormalities in over 10 Mb in size) and three cases (2...
Post a Comment
Read more

Sero-epidemiological study in prediction of the risk groups for measles outbreaks in Vojvodina, Serbia.

Serological survey provides insight grouped age gap measles-specific immunity and the expected prevalence of a certain age. The purpose  Ovine Clia Kits of this study was to describe the sero-epidemiology of measles in Vojvodina before the outbreak in 2017/18 and to discuss preventive measures for the future potential epidemics. A seroprevalence study was conducted from April 2015 to June 2017 by the 3199 serum samples leftovers , The study was conducted prior to the last measles outbreak in Vojvodina which occurred between 12 November 2017 and June 30, 2018. Measles-specific IgG antibodies were determined by using indirect chemiluminescent immunoassay (CLIA) registered participants .Median age was 20 years (IQR 11- 37). Overall, 86.9% of serum samples were seropositive. The highest proportion of measles seronegativity observed in children aged 12-23 months and in adults aged 20-39 years (56.1% and 18.5%, respectively).  The prevalence of measles seronegativity above the WHO...
Post a Comment
Read more

Advances in hemoglobin A1c point of care technology.

Measurement of hemoglobin A1c (A1C) has long been accepted as the best indicator of glucose control over time. A1C tests for the technology used by both differences in costs (high pressure liquid chromatography) or structure (boronate affinity or immunoassay combined with general chemistry). This technology is commonly used in expensive laboratory instruments. More recently, technology A1C has been put into place care (POC) devices, allowing for the availability  Simian Clia Kits of measurement of A1C, greatly facilitate diabetes care in both specialist and general practice.  A1C POC tests must have acceptable performance, standardization of national reference, the National Glycohemoglobin Standardization Program (NGSP) certification, simple operation without the need for expensive instrumentation, and the Clinical Laboratory Improvement Amendments (CLIA) waiver. CLIA-waived POC technologies including Bio-Rad MicroMat II (distributed by a Cholestech GDX) and Axis-Shield Afi...
Post a Comment
Read more